Teva Pharmaceutical Industries (NYSE:TEVA) is back in focus after the U.S. Food and Drug Administration accepted its New Drug Application for ecopipam, a first in class pediatric Tourette syndrome treatment.
Despite the share price easing around 3% over the last day and 2% over the past week, Teva Pharmaceutical Industries has a 1 month share price return of about 4% and a year to date share price return of around 18%, while total shareholder return over the past year is close to 100%. This reflects how investors have reacted to the company's recent pipeline updates, proposed neuroscience acquisitions and legal settlement activity.
Scan for other companies pursuing underappreciated growth stories in healthcare and beyond with our hand picked list of 19 high quality undiscovered gems aligned to similar themes.
After Teva Pharmaceutical Industries nearly doubled shareholders' money over the past year, yet eased off in recent days, the practical question is whether to commit fresh capital now or wait for a pullback. The valuation work comes next.
Teva Pharmaceutical Industries closed at $36.44 compared with a narrative fair value of $40.90. This frames the current discussion around what assumptions sit underneath that gap.
Teva's strategic focus and rapid execution on expanding its innovative branded products (AUSTEDO, AJOVY, UZEDY, and upcoming olanzapine LAI), combined with a robust late-stage pipeline targeting large patient populations, are expected to drive higher-margin topline growth and a more profitable product mix, supporting gross margin and net earnings expansion.
Want to understand why this fair value sits above today's price? The narrative leans on future earnings power, richer margins and a premium profit multiple. The assumptions behind that mix might surprise you.
Result: Fair Value of $40.90 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, Teva Pharmaceutical Industries still faces concentration risk in a handful of branded drugs and a sizeable debt load that could constrain flexibility if conditions worsen.
Find out about the key risks to this Teva Pharmaceutical Industries narrative.
The first fair value of $40.90 points to Teva Pharmaceutical Industries trading at a discount. The P/E picture looks very different. At about 60.1x, the current P/E is far above the US pharmaceuticals industry at 16.7x and the peer average at 19.3x. It is also well above a 34.1x fair ratio. That gap suggests investors risk overpaying if the optimistic earnings path or sentiment cools.
For a closer look at how this pricing gap could shift over time, especially if the market leans back toward that fair ratio, See what the numbers say about this price — find out in our valuation breakdown.
With Teva Pharmaceutical Industries attracting both optimism and caution in this article, consider reviewing the full picture promptly to form your own stance using the 3 key rewards and 2 important warning signs.
If you stop with Teva Pharmaceutical Industries, you might miss other stocks that match your goals. Use focused screeners to quickly surface ideas that fit your style.
Target potential upside in smaller companies by scanning the 22 elite penny stocks with strong financials that pass quality and liquidity filters.
Zero in on value driven ideas by reviewing the 45 high quality undervalued stocks that combine solid fundamentals with discounted pricing.
Prioritize resilience and capital preservation by checking the 75 resilient stocks with low risk scores that score well on financial strength and volatility.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include TEVA.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]